Imtech: European pharmaceutical industry continues to invest in
technology
(Thomson Reuters ONE) - Gouda, the Netherlands - Imtech (technical services provider inEurope) has recently won contracts totalling about 31 million euro todeliver high-tech technological solutions for various pharmaceuticalcompanies in Europe. Imtech notices that the European pharmaceuticalindustry continues to invest structurally in innovative technology.Imtech CEO René van der Bruggen: 'Imtech possesses virtually uniquetechnical competences in the fields of air treatment, clean roomsolutions, energy technology, electrical engineering andinstrumentation. Even during economically difficult circumstances wesee that the European pharmaceutical industry's demand for thesehigh-tech solutions stays buoyant. That is why this industry remainsan important segment for Imtech. Not in the least because variousImtech companies are increasingly co-operating with each other, whichin turn leads to synergy and further growth.'Merck SeronoFor Merck Serono at Corsier-sur-Vevey in Switzerland - the principalbiotechnical production site of Merck Serono - Imtech (ImtechDeutschland) is providing the high-tech technical infrastructure forthe expansion of a biotechnical research and production building.This extension consists of 19 different parts, all dedicated to thespecialised treatment of cancer. Among other things Imtech isdelivering sustainable energy solutions, innovative air treatment andclimate technology, specialised clean room solutions and an extremelyefficient heat recovery system that re-uses 70% of the hourlyproduction of 315,000 m3 of air in order to heat the building and tosupport the primary biotechnical production processes. This includesthe use of high-tech heating pumps in combination with evaporationtechnology, compressed air, water-cooled compressors, absorptiondriers and redundant cooling. With 4,400 hardware and 8,000 softwaremodules for measurement and control, Imtech is integrating all thetechnical facilities to deliver a smoothly working total solution.GlaxoSmithKline BiologicalsFor the GlaxoSmithKline Biologicals sites in Saint-Amand-les-Eauxand Notre-Dame-de-Bondeville in France, Wavre in Belgium and inSingapore, Imtech (Imtech Deutschland) is providing innovative airtreatment solutions in special pharmaceutical isolators that aredeployed to use conditioned air (with optimum air humidity, pressureand temperature geared to the primary processes of GlaxoSmithKlineBiologicals) for sterilisation of parts of the production process.Wyeth Medica and MilliporeFor Wyeth Medica Ireland, a pharmaceutical company acquired byPfizer, Imtech (Imtech Deutschland together with Suir Engineering,Imtech's Irish specialist in electrical engineering andinstrumentation) is providing the complete technological equipment ofseveral clean rooms and research laboratories. The co-operationwithin the Imtech Group enables to deliver an attractive totalsolution to the customer. For the Irish Millipore, a supplier ofspecial medical products for bioscientific research andbiopharmaceutical production, Imtech (Suir Engineering) is providingall the electrical solutions needed for a high-tech facility that canseparate molecules from each other.More informationMedia: Analysts & investors:Pieter Koenders Jeroen LeenaersManager Corporate Communications Manager Investor RelationsT: +31 6 55 74 65 85 T: +31 182 54 35 04E: pieter.koenders(at)imtech.eu E: jeroen.leenaers(at)imtech.euwww.imtech.eu www.imtech.euImtech profileImtech N.V. is a European technical services provider in the fieldsof electrical engineering, ICT and mechanical engineering. With over22,500 employees, Imtech achieves annual revenue of around 3.8billion euro. Imtech holds strong positions in the buildings,industry and infrastructure/traffic markets in the Netherlands,Belgium, Luxembourg, Germany, Eastern Europe, Nordic, the UK, Irelandand Spain and in the global marine market. In total Imtech serves19,500 customers. Imtech offers added value in the form of integratedand multidisciplinary total solutions that lead to better businessprocesses and more efficiency for customers and the customers they,in their turn, serve. Imtech also offers solutions that contributetowards a sustainable society, for example in the areas of energy,the environment, water and mobility. Imtech shares are listed on theEuronext Stock Exchange Amsterdam, where Imtech is included in theMidkap Index. Imtech shares are also included in the Dow Jones STOXX600 index.http://hugin.info/130755/R/1351525/326678.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 02.11.2009 - 07:30 Uhr
Sprache: Deutsch
News-ID 7709
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 256 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Imtech: European pharmaceutical industry continues to invest in
technology"
steht unter der journalistisch-redaktionellen Verantwortung von
Imtech N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
